Mangoceuticals Inc. Announces Warrant Exercises and $193,190 Equity Sale Under ELOC

Reuters
11 Jun
Mangoceuticals Inc. Announces Warrant Exercises and $193,190 Equity Sale Under ELOC

Mangoceuticals Inc. recently completed several share transactions. On June 2, 2025, Abri Advisors Ltd. exercised warrants to purchase 93,731 shares of common stock via a cashless exercise, valuing surrendered shares at $1.50 each. On the same day, Clover Crest Bahamas Ltd. exercised warrants to purchase 131,250 shares of common stock, also through a cashless exercise, at the same per-share value. Additionally, on June 5, 2025, Mangoceuticals sold 100,000 shares of common stock to Platinum Point Capital under an Equity Purchase Agreement for $1.9319 per share, totaling $193,190.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014545), on June 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10